Podcast: Cannabis Causes Schizophrenia? Not So Fast; Pfizer's Weight Loss Drug v. Ozempic

Related articles

A recent study linking marijuana use to schizophrenia attracted widespread attention. Now that the excitement has died down, let's take a closer look at the science. How does Pfizer's weight-loss pill compare to Ozempic, the obesity treatment beloved by celebrities the world over?

Join host Cameron English as he sits down with Dr. Chuck Dinerstein to break down these stories on Episode 43 of the Science Dispatch podcast:

Within the timeframe of the legalization of recreational cannabis, there's been a rise in cannabis “use disorder” and the diagnosis of schizophrenia. It's become a chicken or egg which-came-first problem. A new study suggests cannabis is the gateway, creating 15% of new cases of schizophrenia annually.

If you're one of the 100% of viewers who want to put a brick through your TV when one of the ceaseless, nauseating Ozempic ads comes on there's hope on the horizon. Pfizer has a pill that seems to work as well as the O-O-O-Ozempic injections. Perhaps this will shut up those wretched ads. A look at Pfizer's clinical trial data.

Listen to the Science Dispatch on iTunes Spotify, Stitcher and Google Podcasts. Or add the RSS feed to your favorite podcast app. Join our Dispatch newsletter to get these stories and more delivered to your inbox.